Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1276 - Comparisons of Outcomes of Patients with Advanced Pancreatic Cancer (APC) Treated with FOLFIRINOX (FX) Versus Gemcitabine and Nab-Paclitaxel (GN): A Population-Based Cohort Study.


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Pancreatic Cancer


Neha Papneja


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


N. Papneja1, C. Olson2, H. Chalchal3, M. Moser4, N. Iqbal5, K. Haider5, A. Zaidi5, J. Shaw4, B. Brunet5, D. Dueck5, T. Abbas5, S. Ahmed5

Author affiliations

  • 1 Medicine, University of Saskatchewan, S7N4H4 - Saskatoon/CA
  • 2 Pharmacy, Saskatchewan Cancer Agency, Saskatoon Cancer Center, University of Saskatchewan, S7N4H4 - Saskatoon/CA
  • 3 Oncology, Saskatchewan Cancer Agency, Allan Blair Cancer Center, University of Saskatchewan, S4T7T1 - Regina/CA
  • 4 Surgery, University of Saskatchewan, S7N4H4 - Saskatoon/CA
  • 5 Oncology, Saskatchewan Cancer Agency, Saskatoon Cancer Center, University of Saskatchewan, S7N4H4 - Saskatoon/CA


Abstract 1276


FX and GN are more active than gemcitabine in patients with APC. However, it is not known if FX is superior to GN in APC. In the absence of a randomized controlled trial this population-based cohort study is undertaken to compare efficacy and safety of the two standard regimens in APC.


All patients with newly diagnosed locally APC in the province of Saskatchewan, Canada, during 2011-2016 who received FX or GN, were assessed. A Cox proportional multivariate analysis was done to evaluate correlation of chemotherapy regimen and survival.


119 eligible patients with median age of 61 yrs (IQR:56-67) & M:F of 70:49 were identified. 93% had WHO performance status (PS) of 0 or 1, and 77% had metastatic PC. 15% received adjuvant therapy and 33% had ≥2 metastatic sites. Of 119 patients, 86 (72%) received FX and 33 (28%) treated with GN. There were significant differences between the two groups with respect to age (59 vs. 64 yrs), WHO PS of 2 (2% vs. 15%) and metastatic disease (81% vs. 64%), in FX and GN groups, respectively. Median progression-free survival of FX group was 6 months (95%CI: 4.5-7.5) vs. 4 months (2.9-5.1) with GN (p = 0.39). Median overall survival (OS) with FX was 9 months (7-11) vs. 9 months (4.2-13.8) with GN (p = 0.88). At 12 months 26% & 27% patients were alive in FX and GN groups, respectively. Median OS of patients who received 2nd line therapy was 15 months (10.5-19.5) vs. 8 months (6.3-9.7) with no 2nd line therapy (0.009). Patients in FX had higher incidences of any grade diarrhea (52% vs.18%), mucositis (21 vs. 3), neuropathy (63 vs.36) and thromboembolism (34 vs. 9) whereas patients in GN group had more often fatigue (66 vs.79) and thrombocytopenia (48 vs. 57). On multivariate analysis normal albumin, HR:0.63 (0.41-0.97), male sex, HR:0.65 (0.43-0.97) and 2nd line therapy, HR:0.50 (0.28-0.86) were correlated with better survival but no correlation between FX or GN and survival was noted.


Our results showed that real world patients with APC treated with FX or GN had comparable survival with different safety profiles. In this selected patients who received combination therapy, male gender and subsequent treatment were correlated with better survival.

Clinical trial identification

Not applicable

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.